Krauss, John

Entrectinib in Patients with Advanced or Metastatic NTRK Fusion-Positive Solid Tumours: Integrated Analysis of Three Phase 1-2 Trials

Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology

Lung Cancer Treatments and MutationsSarcoma Diagnosis and Treatment

Cited by 1,790

KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 1,733

Fruquintinib versus Placebo in Patients with Refractory Metastatic Colorectal Cancer (FRESCO-2): An International, Multicentre, Randomised, Double-Blind, Phase 3 Study

Dasari, A., Lonardi, S., Garcia-Carbonero, R., Elez, E., Yoshino, T., Sobrero, A., Yao, J., García-Alfonso, P., Kocsis, J., Cubillo Gracian, A., et al. (2023) · The Lancet

Colorectal Cancer Treatments and StudiesAngiogenesis and VEGF in Cancer

Cited by 368

Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial

Fakih, M. G., Kopetz, S., Kuboki, Y., Kim, T. W., Munster, P. N., Krauss, J. C., Falchook, G. S., Han, S.-W., Heinemann, V., Muro, K., et al. (2022) · The Lancet Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 320

Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial

Kuboki, Y., Fakih, M., Strickler, J., Yaeger, R., Masuishi, T., Kim, E. J., Bestvina, C. M., Kopetz, S., Falchook, G. S., Langer, C., et al. (2024) · Nature Medicine

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 103

OA03.03 sotorasib in combination with RMC-4630, a SHP2 inhibitor, in KRAS p.G12C-mutated NSCLC and other solid tumors

Falchook, G., Li, B. T., Marrone, K. A., Bestvina, C. M., Langer, C. J., Krauss, J. C., Strickler, J. H., Meloni, A., Dai, T., Varrieur, T., et al. (2022) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsProtein Tyrosine Phosphatases

Cited by 56

Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours

Govindan, R., Fakih, M. G., Price, T. J., Falchook, G. S., Desai, J., Kuo, J. C., Strickler, J. H., Krauss, J. C., Li, B. T., Denlinger, C. S., et al. (2019) · Annals of Oncology

Lung Cancer Treatments and MutationsMelanoma and MAPK Pathways

Cited by 40

Abstract P05-02: A phase 1b study evaluating the combination of sotorasib, a KRASG12C inhibitor, and afatinib, a pan-ErbB tyrosine kinase inhibitor, in advanced KRAS p.G12C mutated non-small cell lung cancer (NSCLC)

Gandara, D., Marrone, K., Govindan, R., Skoulidis, F., Durm, G., Clarke, J., Frank, R., Krauss, J., Snyder, W., Dai, T., et al. (2021) · Molecular Cancer Therapeutics

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 24

45MO Sotorasib in Combination with Panitumumab in Refractory KRAS G12C-Mutated Colorectal Cancer: Safety and Efficacy for Phase Ib Full Expansion Cohort

Kuboki, Y., Yaeger, R., Fakih, M., Strickler, J. H., Masuishi, T., Kim, E. J.-H., Bestvina, C. M., Langer, C. J., Krauss, J. C., Puri, S., et al. (2022) · Annals of Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 20